<DOC>
	<DOCNO>NCT02280356</DOCNO>
	<brief_summary>The purpose study test safety side effect `` `` ultra-hypofractionated '' radiation therapy use brachytherapy ( radiation implant ) . This treatment deliver high radiation dose treatment short period time .</brief_summary>
	<brief_title>Radiation Therapy Combination With Brachytherapy Clinically Localized , Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Intermediate risk prostate cancer patient eligible study . Intermediate risk group assess per NCCN guideline : Pathologicallyproven diagnosis prostate adenocarcinoma PSA 1020ng/mL Gleason =7 Clinical stage T2b/c Clinical stage T2b/c Additionally , patient require meet follow criterion Age ≥18 KPS≥70 Prostate volume ≤ 60cc ( cytoreductive androgen deprivation therapy prior brachytherapy ≤ 6 month duration allow achieve goal ) . For patient prostate volume 5060ccs , hormone therapy discretion physician . International Prostate Symptom Score ≤15 Prior prostate surgery ( include TURP ) Prior history chronic prostatitis urethral stricture Inflammatory bowel disease Prior history pelvic radiotherapy Unable give inform consent Metastatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiation Therapy</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>14-163</keyword>
</DOC>